VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agentsDavid F. Stojdl, John C. Bell, Brian D. Lichty et al.|Cancer Cell|2003Cited by 850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virusDavid F. Stojdl, John C. Bell, Brian D. Lichty et al.|Nature Medicine|2000Cited by 816
Targeting Tumor Vasculature With an Oncolytic VirusCaroline J. Breitbach, John C. Bell, Theresa Falls et al.|Molecular Therapy|2011Cited by 202
Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activityCarolina S. Ilkow, John C. Bell, Monique Marguerie et al.|Nature Medicine|2015Cited by 169
A let-7 MicroRNA-sensitive Vesicular Stomatitis Virus Demonstrates Tumor-specific ReplicationRobert E. Edge, John C. Bell, Theresa Falls et al.|Molecular Therapy|2008Cited by 135